Updating results

78 results

Sort: Relevance | Date

Gosuranemab for treating progressive supranuclear palsy [ID1607]

Proposed [GID-TA10553] Expected publication date: TBC

Technology appraisal guidance Proposed

Omalizumab for treating chronic rhinosinusitis with nasal polyps [ID1650]

Proposed [GID-TA10558] Expected publication date: TBC

Technology appraisal guidance Proposed

Ponesimod for treating relapsing multiple sclerosis [ID1393]

Proposed [GID-TA10556] Expected publication date: TBC

Technology appraisal guidance Proposed

Ofatumumab for treating relapsing multiple sclerosis [ID1677]

Proposed [GID-TA10557] Expected publication date: TBC

Technology appraisal guidance Proposed

Treosulfan with fludarabine for non-malignant disease before allogeneic stem cell transplant [ID1540]

Proposed [GID-TA10453] Expected publication date: TBC

Technology appraisal guidance Proposed

Nintedanib for treating progressive fibrosing interstitial lung disease [ID1599]

Proposed [GID-TA10520] Expected publication date: TBC

Technology appraisal guidance Proposed

Dulaglutide for treating type 2 diabetes [ID1451]

Proposed [GID-TA10439] Expected publication date: TBC

Technology appraisal guidance Proposed

Crizanlizumab for preventing sickle cell crises in sickle cell disease [ID1406]

Proposed [GID-TA10470] Expected publication date: 24 March 2021

Technology appraisal guidance Proposed

Upadacitinib for treating moderate to severe rheumatoid arthritis [ID1400]

Proposed [GID-TA10389] Expected publication date: 18 March 2020

Technology appraisal guidance Proposed

Imlifidase for preventing kidney transplant rejection in people with chronic kidney disease [ID1672]

Proposed [GID-TA10552] Expected publication date: TBC

Technology appraisal guidance Proposed

Vericiguat for treating chronic heart failure with reduced ejection fraction [ID2731]

Proposed [GID-TA10595] Expected publication date: TBC

Technology appraisal guidance Proposed

Tralokinumab for treating moderate to severe atopic dermatitis [ID3734]

Proposed [GID-TA10596] Expected publication date: TBC

Technology appraisal guidance Proposed

Upadacitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3733]

Proposed [GID-TA10597] Expected publication date: TBC

Technology appraisal guidance Proposed

Secukinumab for treating active enthesitis-related arthritis and juvenile psoriatic arthritis in people aged 2 to 18 [ID3738]

Proposed [GID-TA10598] Expected publication date: TBC

Technology appraisal guidance Proposed

Treosulfan with fludarabine before allogeneic stem cell transplant for people aged under 18 with non-malignant diseases [ID3745]

Proposed [GID-TA10599] Expected publication date: TBC

Technology appraisal guidance Proposed

Filgotinib for treating moderately to severely active ulcerative colitis [ID3736]

Proposed [GID-TA10600] Expected publication date: TBC

Technology appraisal guidance Proposed

Ruxolitinib for treating acute graft versus host disease refractory to corticosteroids in people aged 12 and over [ID2715]

Proposed [GID-TA10601] Expected publication date: TBC

Technology appraisal guidance Proposed

Ruxolitinib for treating chronic graft versus host disease refractory to corticosteroids in people aged 12 and over [ID2716]

Proposed [GID-TA10602] Expected publication date: TBC

Technology appraisal guidance Proposed

Palovarotene for preventing heterotopic ossification associated with fibrodysplasia ossificans progressiva [ID3739]

Proposed [GID-TA10603] Expected publication date: TBC

Technology appraisal guidance Proposed

Cabotegravir with rilpivirine for the oral treatment of HIV-1 [ID3731]

Proposed [GID-TA10604] Expected publication date: TBC

Technology appraisal guidance Proposed

Fostemsavir for treating multidrug resistant HIV-1 [ID2726]

Proposed [GID-TA10605] Expected publication date: TBC

Technology appraisal guidance Proposed

Avalglucosidase alfa for treating late-onset glycogen storage disease type II [ID3737]

Proposed [GID-TA10594] Expected publication date: TBC

Technology appraisal guidance Proposed

Solriamfetol for treating excessive waketime sleepiness caused by narcolepsy [ID1602]

Proposed [GID-TA10524] Expected publication date: 16 September 2020

Technology appraisal guidance Proposed

Elexacaftor, tezacaftor and ivacaftor fixed dose combination therapy for treating cystic fibrosis with the F508del mutation [ID1661]

Proposed [GID-TA10566] Expected publication date: TBC

Technology appraisal guidance Proposed

Obeticholic acid for treating liver fibrosis in people with steatohepatitis [1645]

Proposed [GID-TA10606] Expected publication date: TBC

Technology appraisal guidance Proposed

Ravulizumab for treating atypical haemolytic uraemic syndrome (aHUS) [ID1530]

Proposed [GID-TA10564] Expected publication date: TBC

Technology appraisal guidance Proposed

Pexidartinib for treating symptomatic tenosynovial giant cell tumour [ID1682]

Proposed [GID-TA10609] Expected publication date: TBC

Technology appraisal guidance Proposed

Roxadustat for treating anaemia in people with chronic kidney disease [ID1483]

Proposed [GID-TA10610] Expected publication date: TBC

Technology appraisal guidance Proposed